Independent · Evidence-led · We don't sell peptides
EU / NordicsUpdated weeklyEN

Explore this article's sources with AI

ChatGPTClaudePerplexityGeminiGrokGoogle AI

Follow PeptideMethods on Google

First published

Semaglutide in Hemodialysis Study

A 2026 target-trial emulation associated semaglutide with lower mortality and hospitalization than pooled comparators, without proving causation.

Why we wrote this. Dialysis populations are often missing from randomized trials. This readout preserves the value and causal limits of a target-trial emulation.

In this article (5 sections)
  1. The study used a target-trial emulation
  2. Mortality and hospitalization were lower in the combined comparison
  3. The comparator-specific results were not identical
  4. What this result should change
  5. What we don't yet know

A 2026 observational study from the United States compared semaglutide with dulaglutide or liraglutide in people with diabetes receiving maintenance hemodialysis. After statistical weighting, semaglutide use was associated with lower one-year mortality on dialysis, fewer all-cause hospitalizations and somewhat greater weight loss[1]. The study emulated a target trial from health records. It did not randomly assign treatment, so the associations do not prove that semaglutide caused the differences.

People receiving hemodialysis are often excluded from randomized drug trials, leaving clinicians with limited comparative evidence. This study addresses that real evidence gap with United States Renal Data System and Medicare data from 2011 through 2022. Its strength is a large real-world cohort in a specific high-risk population; its main limitation is the lack of random assignment.

The study used a target-trial emulation

Researchers identified new users of the compared GLP-1 receptor agonists and designed the analysis to resemble a hypothetical trial. They used overlap weighting to balance measured differences between treatment groups. The weighted effective sample size was 3,200 patients, with a mean age of 61 years and median follow-up of 1.1 years[2].

The weighted cohort was 52% male, 63% White and 28% Black. Median body mass index was 34 kg/m². These descriptors help readers judge who contributed data, but they do not show that every dialysis patient would have the same outcome. The authors limited their conclusion to patients with diabetes on hemodialysis for whom there was clinical equipoise between the compared medicines.

Overlap weighting can make groups more similar on recorded characteristics. It cannot balance variables that were absent, inaccurately coded or not recognized as confounders. Prescribing choices may reflect frailty, gastrointestinal tolerance, clinician preference, access and other factors tied to outcomes. That distinction is critical: target-trial emulation is not the same as a randomized target trial.

Mortality and hospitalization were lower in the combined comparison

For death while on dialysis, semaglutide versus the combined dulaglutide-or-liraglutide group had a subdistribution hazard ratio of 0.82, with a 95% confidence interval from 0.70 to 0.97. One-year cumulative incidence was 11% with semaglutide and 13% with the comparators[1]. A hazard ratio describes relative event timing in the model. The two-percentage-point cumulative-incidence difference supplies the more concrete one-year comparison.

All-cause hospitalization had a subdistribution hazard ratio of 0.91, with a 95% confidence interval from 0.83 to 0.99. Reported one-year incidence was 57% versus 62%[2]. The confidence interval sat close to 1, and hospitalization remained common in both groups. The result should not be described as preventing hospitalization for an individual patient.

Fine-Gray models accounted for competing events in the time-to-event analyses, a relevant choice because death, transplantation or other events can alter whether an outcome remains observable in a dialysis population; statistical sophistication improves the comparison, but it does not remove residual confounding or errors inherited from claims data.

The comparator-specific results were not identical

Direct comparison with dulaglutide produced similar associations: the mortality hazard ratio was 0.82 and the hospitalization hazard ratio was 0.88. By contrast, semaglutide versus liraglutide showed no statistically significant benefit for mortality or hospitalization[1]. That split matters because a pooled comparator can hide differences between its components.

The abstract does not provide the liraglutide-specific point estimates, confidence intervals or patient counts. Precision is unknown. Readers therefore cannot tell whether the null result reflects similar outcomes, a smaller subgroup with low precision or both. The finding does not establish that semaglutide is superior to every other GLP-1 medicine in dialysis.

At one year, estimated body-weight change was minus 4.8% with semaglutide and minus 3.4% with dulaglutide or liraglutide[2]. Weight change in hemodialysis needs careful interpretation because fluid status and nutritional health can affect measured weight. The semaglutide research overview places this population-specific result beside evidence from other settings.

What this result should change

The paper offers comparative evidence for a group that is difficult to study, not a prescription rule. Medicine selection in hemodialysis can depend on treatment goals, tolerability, glucose control, nutritional status, other illnesses and access. The authors' statement that semaglutide may be preferred compared with dulaglutide applies to the analyzed setting and remains an observational interpretation.

Patients should not switch GLP-1 medicines on the basis of this article alone. A nephrology and diabetes care team can interpret the findings alongside an individual's dialysis course and medicine history. Our semaglutide safety section gives general context but does not replace dialysis-specific clinical review.

What we don't yet know

Important gaps remain because the abstract does not report discontinuation, adverse events, glycemic outcomes or reasons for treatment selection. Median follow-up was just over one year, so longer-term comparative outcomes remain uncertain. Claims-based definitions may miss clinical detail, and the data period ended in 2022. Changes in prescribing since then may affect how closely the cohort reflects current practice.

A randomized comparison would offer stronger causal evidence, though recruitment in this population can be difficult and such a trial has not happened. Until that evidence exists, this target-trial emulation is useful for hypothesis testing and shared clinical discussion. Its results should remain association language, with the combined and medicine-specific comparator findings kept separate.

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.

Frequently asked

Was this a randomized trial?

Researchers did not randomly assign treatment; they emulated a target trial with U.S. registry and Medicare data and used statistical weighting, although unmeasured confounding can remain.

What was the one-year mortality result?

Cumulative mortality on dialysis was 11% with semaglutide and 13% with pooled dulaglutide or liraglutide. The adjusted subdistribution hazard ratio was 0.82.

Was semaglutide better than both comparators separately?

The dulaglutide comparison was similar to the pooled result, but the liraglutide comparison did not show a statistically significant mortality or hospitalization benefit.

Should a dialysis patient switch medicines because of this study?

This evidence alone should not prompt a switch; treatment decisions require individualized review by the patient's nephrology and diabetes care team.

Sources

  1. [1]Target Trial of Semaglutide Versus Dulaglutide or Liraglutide in Patients Receiving Hemodialysis. Diabetes Care. 2026. PMID 42937520.Tier 1 · primary↩
  2. [2]NCBI PubMed EFetch record and abstract for PMID 42937520Tier 1 · primary↩

No revisions yet. First published .

About the editorial team

PeptideMethods is written and edited by the PeptideMethods Editorial Team and published by Digital Compass Group Ltd. The team is not made up of medical professionals; every health, regulatory or dosage claim on the site is tied to a primary source and is not a substitute for advice from a qualified clinician.

See our editorial policy and methodology for how we research, source and verify.

Read the pillars